Plaintiff
1 case as plaintiff.
I'll verify the company's profile with web search.
Louisiana Health Service & Indemnity Company — commonly doing business as Blue Cross and Blue Shield of Louisiana and rebranded as Louisiana Blue in 2024 — is a tax-paying, not-for-profit mutual health insurer owned by its policyholders rather than shareholders (lablue.com; company economic-impact fact sheet). It was founded in New Orleans in 1934 as the Hospital Service Association of New Orleans and is headquartered at 5525 Reitz Ave., Baton Rouge, Louisiana. It is an independent licensee of the Blue Cross Blue Shield Association, licensed to sell only in Louisiana, and remains independent after a proposed sale to Elevance Health was withdrawn in February 2024 (Louisiana Department of Insurance; AP). Reported headcount runs roughly 2,500–3,500 employees, with about 1.9 million members and total revenue around $3.3 billion in 2023 (company fact sheet; WBRZ; ThinkAdvisor). It is not publicly traded.
The company sells medical, dental, Medicare Advantage and prescription-drug coverage to individuals, families and employer groups, and provides third-party administrative services for self-funded employer plans (PitchBook; Mergr). It also contracts with most Louisiana providers and operates subsidiaries including HMO Louisiana, Inc. and Southern National Life Insurance Company, and co-owns the Healthy Blue Medicaid/Medicare dual-eligible plan with Elevance (company fact sheet).
Litigation posture: this is an operating company, not a patent assertion entity. In the tracked data it appears once, solely as a plaintiff and never as a defendant — a pattern inconsistent with an NPE. Its single case is not a patent-infringement suit brought by the company but a purchaser-side antitrust class action, and it was filed in the S.D.N.Y., not a plaintiff-friendly patent venue such as the Eastern District of Texas.
Notable case: Louisiana Health Service & Indemnity Co. v. Celgene Corp. (S.D.N.Y., filed Sept. 5, 2023, No. 1:23-cv-07871), a putative class action with HMO Louisiana and an individual plaintiff against Celgene, Bristol Myers Squibb and two individuals. Plaintiffs allege fraud on the PTO, sham patent litigation and reverse-payment settlements delaying generic pomalidomide (Pomalyst); Hagens Berman is class counsel. The court granted dismissal in March 2025, entered judgment for defendants on April 10, 2026, and plaintiffs have sought Second Circuit review. No merits assessment is offered here.
Antitrust action in which the '428 patent is cited as part of the challenged Celgene patent portfolio; Blue Cross LA sued Celgene in S.D.N.Y. Status is generally pending/consolidated.